A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g

An Open Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00096603

Enrollment

450

Registered

2004-11-15

Start date

2002-10-31

Completion date

2004-07-31

Last updated

2014-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Keywords

Moderate to severe plaque psoriasis

Brief summary

This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in Study ACD2600g.

Interventions

DRUGRaptiva (efalizumab)

Study design

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Signed informed consent * Previous participation in Study ACD2600g * For women of childbearing potential, continued use of an acceptable method of contraception for the duration of the study

Exclusion criteria

* Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to Efalizumab

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026